China Reform Holdings Co., Ltd. has led a RMB670 million (US$101 million) new funding round in 3D Medicines, a Chinese healthcare firm developing precision medicine for cancer treatment. China Reform Holdings made the investment via China State-Owned Assets Venture Investment Fund, a policy fund established last year with target size of RMB200 billion (US$30 billion). ChinaEquity Group and a number of unnamed investors also participated in the round, according to a company announcement. “Currently, when Chinese people are diagnosed with …

China Reform Holdings Leads $101M Round In Chinese Precision Medicine Firm 3D Medicines appeared first on China Money Network.